Detailed information for compound 50621
Basic information
Technical information
- TDR Targets ID: 50621
- Name: 2-amino-8-bromo-9-(2-hydroxyethoxymethyl)-3H- purin-6-one
- MW: 304.101 | Formula: C8H10BrN5O3
-
H donors: 3
H acceptors: 3
LogP: -0.9
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: OCCOCn1c(Br)nc2c1nc(N)[nH]c2=O
- InChi: 1S/C8H10BrN5O3/c9-7-11-4-5(12-8(10)13-6(4)16)14(7)3-17-2-1-15/h15H,1-3H2,(H3,10,12,13,16)
- InChiKey: GBMIHDMGBMQYBU-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 2-azanyl-8-bromo-9-(2-hydroxyethoxymethyl)-3H-purin-6-one
- 8-hydroxyacyclovir
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | purine nucleoside phosphorylase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Trypanosoma brucei | methylthioadenosine phosphorylase, putative | purine nucleoside phosphorylase | 289 aa | 255 aa | 23.1 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Schistosoma mansoni | purine nucleoside phosphorylase | 0.0154 | 1 | 0.5 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0122 | 0 | 0.5 |
| Mycobacterium ulcerans | purine nucleoside phosphorylase | 0.0154 | 1 | 0.5 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Mycobacterium leprae | Probable purine nucleoside phosphorylase DeoD (INOSINE PHOSPHORYLASE) (PNP) | 0.0154 | 1 | 0.5 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Schistosoma mansoni | purine nucleoside phosphorylase | 0.0154 | 1 | 0.5 |
| Mycobacterium tuberculosis | Probable purine nucleoside phosphorylase DeoD (inosine phosphorylase) (PNP) | 0.0154 | 1 | 0.5 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Giardia lamblia | Purine nucleoside phosphorylase lateral transfer candidate | 0.0154 | 1 | 0.5 |
| Trichomonas vaginalis | purine nucleoside phosphorylase I, putative | 0.0154 | 1 | 0.5 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus granulosus | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Echinococcus multilocularis | purine nucleoside phosphorylase | 0.0154 | 1 | 1 |
| Onchocerca volvulus | Purine nucleoside phosphorylase homolog | 0.0154 | 1 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Antiviral index (functional) | = 450 | Ratio of ID50 for dThd or dUrd incorporation to ID50 for HSV-1, HSV-2 or VV(whatever was lowest) | ChEMBL. | 6092636 |
| IC50 (ADMET) | > 200 uM | Cytotoxicity against mouse L1210/0 cells after 48 hrs | ChEMBL. | 17341060 |
| ID50 (functional) | = 0.5 ug ml-1 | Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells | ChEMBL. | 6092636 |
| ID50 (functional) | = 0.5 ug ml-1 | Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells | ChEMBL. | 6092636 |
| ID50 (functional) | = 225 ug ml-1 | Inhibitory concentration required to reduce incorporation of 2-deoxyuridine (dUrd) into DNA of Primary Rabbit kidney (PRK) cell cultures | ChEMBL. | 6092636 |
| ID50 (functional) | = 340 ug ml-1 | Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures | ChEMBL. | 6092636 |
| ID50 (functional) | = 355 ug ml-1 | Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells | ChEMBL. | 6092636 |
| ID50 (functional) | = 355 ug ml-1 | Inhibitory concentration required to reduce cell growth of Murine Leukemia L1210 cells | ChEMBL. | 6092636 |
| ID50 (functional) | > 400 ug ml-1 | Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells | ChEMBL. | 6092636 |
| ID50 (functional) | > 400 ug ml-1 | Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells | ChEMBL. | 6092636 |
| ID50 (functional) | > 500 ug ml-1 | Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells | ChEMBL. | 6092636 |
| ID50 (functional) | > 500 ug ml-1 | Inhibitory concentration required to reduce [3H1',2']dUrd incorporation into cellularDNA by 50 % | ChEMBL. | 6092636 |
| ID50 (functional) | > 500 ug ml-1 | Inhibitory concentration required to reduce [3H-methyl]-dThd C incorporation into cellular DNA by 50% in Murine Leukemia L1210 cells | ChEMBL. | 6092636 |
| ID50 (functional) | > 500 ug ml-1 | Inhibitory concentration required to reduce [3H1',2']dUrd incorporation into cellularDNA by 50 % | ChEMBL. | 6092636 |
| Ki (binding) | = 18.7 uM | PNP activity in human RBC | ChEMBL. | 8478902 |
| Ki (binding) | = 18.7 uM | PNP activity in human RBC | ChEMBL. | 8478902 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- Search by CAS
- ChEMBL: CHEMBL223508
- PubChem: 512560
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.